Visual field testing in NAION patients reveals various patterns of vision loss, though altitudinal defects affecting either the superior or inferior visual field occur most commonly
If you inhibit glucagon secretion, you will also make blood glucose go down, because you then inhibit the production of glucose in the body
Appetite changes noticeable but weight loss modest you're still on a low starting dose Months 23: 1018 lbs total for many patients as doses increase and appetite suppression strengthens Months 46: 2030 lbs total for patients at or near therapeutic dose
People who stop taking it often gain the weight back, though some are able to maintain their weight loss without the drugs, or with a less frequent injection
Off-Label Use: Risks Without a Data Foundation Some families and clinicians seek GLP-1 receptor agonist therapy for children under 12 with severe obesity, particularly when lifestyle interventions have not produced sufficient weight reduction and comorbidities like type 2 diabetes or obstructive sleep apnea are present